Strides Pharma Science Ltd

- There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript excerpts. - The company is focusing on balance sheet discipline and has reduced net debt by Rs. 169 crores on a constant currency basis over 9 months. - Net debt stands at Rs. 1,436 crores with an improved EBITDA to net debt ratio of 1.59x, indicating strengthening financial health. - The company invested Rs. 284 crores in CAPEX and product rights, funded through operational cash flows (operating cash of Rs. 484 crores over 9 months). - Management emphasizes improving profitability and maintaining targeted debt/EBITDA ratios but does not discuss raising fresh funds via debt or equity. - Overall, priority is on sustainable growth and balance sheet strength rather than immediate external fundraising.

- Maintenance CAPEX is on track in the range of Rs. 100 crore to Rs. 125 crore. - Additional CAPEX includes opportunistic targeted purchases of global rights for both US and Ex-US markets, though no specific numbers are provided. - Rs. 284 crores invested in CAPEX for tangible and intangible assets during the 9-month period. - Investments are aimed at driving growth in both the US and Ex-US markets. - The company plans to continue investing in R&D programs, expected to start delivering revenue in the next 12 to 18 months. - Focus remains on balancing CAPEX between maintenance and growth opportunities without compromising on profitability.

- Strides Pharma aims to achieve around $400 million revenue from the US market by FY'28, with growth expected over the next 9 quarters. - Ex-US markets (other regulated and growth markets) are growing faster than anticipated, now contributing 47% of Q3 FY'26 revenues with 20% YoY growth; the gap between US and Ex-US revenues has significantly narrowed. - Growth drivers include ramping up dormant products, control substances normalizing, investing in complex generics like nasal sprays and 505(b)(2) programs, and expanding product portfolios within existing geographies. - The company foresees consistent growth rather than quarter-to-quarter spikes, with multiple levers in place across markets. - Planned launches and portfolio expansions will sustain growth; the focus remains on profitability and EBITDA margin expansion. - The regulatory pathway and customer base in Ex-US markets are mature, supporting steady growth. - Industry-wide pricing pressure remains, but improved cost of goods sold helps maintain margins.

- The company aims to reach US revenues of $400 million by FY'28 with consistent growth expected over the next 2 years. - Operational PAT grew 65% in the 9-month period with an operational EPS of Rs. 41.5, already exceeding FY'25 full-year operational PAT. - EBITDA margins have improved by 180 basis points from FY'25 and operating leverage is expected to continue as under-recoveries reduce. - Focus remains on EBITDA margin expansion, with profitability thresholds guiding product portfolio decisions. - Tax rate is expected to be in the 15% to 20% range over the next couple of years. - Investments in R&D, product acquisitions, and expansion in ex-US regulated markets are key drivers. - Operational PAT margin for the quarter was at 10.7%, with continued focus on balancing growth and profitability. - The company expects consistent growth from Ex-US markets and a steady ramp-up from the US business driven by dormant products and control substances normalizing.

- Order book in access market currently subdued due to reduced donor funding, especially from large institutions like the Global Fund. - Several countries have lowered their contributions, causing a significant reduction in orders not only for Strides but industry-wide. - Allocation periods are rolling over as donors have not fulfilled obligations. - Some countries are increasing contributions to fill funding gaps caused by others, but the gap remains large. - Near-term outlook for access market orders is muted. - Expectation that donor funding and order volumes will improve or "ameliorate" gradually in the near future.